WuXi Biologics facility passed GMP inspection with zero critical findings, leading to EMA support for EU marketing authorization.

3 reports, 3 independent Updated Jun 18

Gone quiet Reached 3 outlets in its first 24 hours

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

WuXi Biologics facility passed GMP inspection with zero critical findings, leading to EMA support for EU marketing authorization.

Who's involved

What this event is mainly about

WuXi Biologics European Medicines Agency

Keep exploring

Part of

WuXi Biologics maintains operational bases in China and leverages a global CRDMO network for client support. All 2 developments

The entities involved

WuXi Biologics
Chinese pharmaceutical company
- WuXi Biologics received EMA approval and successfully passed FDA GMP inspection.Thu 14:29
European Medicines Agency
highest regulatory authority on medicines in the European Union
- IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.Mon 14:18
- Both the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Fri 23:04

Coverage

Newest first; wire copies grouped